Born in 2013 from the separation from Abbott, AbbVie recently acquired Shire for $ 53,52 bln. Shire’s stakeholders will maintain control over the 25 per cent of the new company. The combined market cap counts for $ 137 bln, covering more than 170 countries, with 14 manufacturing facilities, 9 R&D centres and more than 30K employees.
The merger will give raise to six combined areas of expertise, including oncology, immunology, neuroscience, liver disease/virology and rare diseases. The combination of the portfolios account for nine leading products in the market, more that twenty projects in late phase or registration and more than thirty early development projects.